Sugi Predict

Sugi Predict / Compounds / SCHEMBL407651

SCHEMBL407651

SCHEMBL407651

CCOC(=O)C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 1/20 0.64
▸ MET P08581 15/20 0.63
▸ AXL P30530 5/20 0.63
▸ KDR P35968 3/20 0.63
▸ FLT3 P36888 3/20 0.61
▸ AURKA O14965 1/20 0.59
▸ ABL1 P00519 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ SRC P12931 1/20 0.59
▸ FER P16591 1/20 0.59
▸ CDK8 P49336 1/20 0.59
▸ TYRO3 Q06418 1/20 0.59
▸ MERTK Q12866 1/20 0.59
▸ MAP2K5 Q13163 1/20 0.59
▸ AURKB Q96GD4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693530 1.00 PDGFRA (0.64) PDGFRAMETAXLKDRFLT3
SCHEMBL371919 0.88 PDGFRA (0.66) PDGFRAMETAXLKDRFLT3
SCHEMBL19373219 0.87 PDGFRA (0.69) PDGFRAMETAXLKDRFLT3
SCHEMBL2744790 0.87 PDGFRA (0.69) PDGFRAMETAXLKDRFLT3
SCHEMBL371539 0.85 MET (0.70) PDGFRAMETAXLKDRAURKA
SCHEMBL20525878 0.85 PDGFRA (0.47) PDGFRAMETAXLKDRFLT3
SCHEMBL5056203 0.85 PDGFRA (0.72) PDGFRAMETAXLKDRFLT3
SCHEMBL3113049 0.84 PDGFRA (0.71) PDGFRAMETAXLKDRFLT3
SCHEMBL4401175 0.82 MET (0.76) PDGFRAMETAXLKDRFLT3
SCHEMBL14971061 0.82 AXL (0.59) PDGFRAMETAXLKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US disclosed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 PDGFRA 173/4885MET 2/4885AXL 239/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 PDGFRA 182/4885MET 2/4885AXL 241/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 PDGFRA 182/4885MET 2/4885AXL 241/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 PDGFRA 182/4885MET 2/4885AXL 241/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET PDGFRA 63/4885MET 3/4885AXL 109/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 PDGFRA 173/4885MET 2/4885AXL 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.